These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31754710)

  • 21. Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study.
    Fuchs A; Rotzinger A; Cavassini M; Bugnon O; Buclin T; Schneider MP; Csajka C
    Ther Drug Monit; 2016 Aug; 38(4):506-15. PubMed ID: 26937748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum Nevirapine and Efavirenz concentrations and effect of concomitant rifampicin in HIV infected children on antiretroviral therapy.
    Shah I; Swaminathan S; Ramachandran G; Kumar AK; Goray A; Chaddha U; Tayal S; Lala M
    Indian Pediatr; 2011 Dec; 48(12):943-7. PubMed ID: 21555806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and Safety Profile of Artesunate-Amodiaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults.
    Banda CG; Dzinjalamala F; Mukaka M; Mallewa J; Maiden V; Terlouw DJ; Lalloo DG; Khoo SH; Mwapasa V
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benefits and Limits of Antiretroviral Drug Monitoring in Routine Practice.
    Maitre T; Muret P; Blot M; Waldner A; Duong M; Si-Mohammed A; Chavanet P; Aho S; Piroth L
    Curr HIV Res; 2019; 17(3):190-197. PubMed ID: 31490758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?
    Dahri K; Ensom MH
    Clin Pharmacokinet; 2007; 46(2):109-32. PubMed ID: 17253884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes?
    Orrell C; Cohen K; Leisegang R; Bangsberg DR; Wood R; Maartens G
    AIDS Res Ther; 2017 Apr; 14(1):20. PubMed ID: 28376815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
    Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A;
    Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Very early virological failure and drug resistance mutations in a woman on antiretroviral therapy in Eastern Cape, South Africa: a case report.
    Sogbanmu OO; Adeniyi OV; Fuentes YO; Ter Goon D
    J Med Case Rep; 2015 May; 9():106. PubMed ID: 25947544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
    ; de Vincenzi I
    Lancet Infect Dis; 2011 Mar; 11(3):171-80. PubMed ID: 21237718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy.
    Court R; Gordon M; Cohen K; Stewart A; Gosnell B; Wiesner L; Maartens G
    Int J Antimicrob Agents; 2016 Aug; 48(2):158-62. PubMed ID: 27345268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women.
    Vieira CS; Bahamondes MV; de Souza RM; Brito MB; Rocha Prandini TR; Amaral E; Bahamondes L; Duarte G; Quintana SM; Scaranari C; Ferriani RA
    J Acquir Immune Defic Syndr; 2014 Aug; 66(4):378-85. PubMed ID: 24798768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-measurement therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, lamivudine, efavirenz, nevirapine, lopinavir and nelfinavir.
    Donnerer J; Haas BJ; Kessler HH
    Pharmacology; 2008; 82(4):287-92. PubMed ID: 18931536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria.
    Usman SO; Oreagba IA; Akinyede AA; Agbaje EO; Akinleye MO; Onwujuobi AG; Ken-Owotor C; Adeuja O; Ogunfowokan T; Kogbe S; Owolabi ET; Adeniji H; Busari AW; Hassan OO; Abideen G; Akanmu AS
    J Pharmacol Sci; 2020 Nov; 144(3):95-101. PubMed ID: 32921396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.
    Bergshoeff AS; Fraaij PL; Ndagijimana J; Verweel G; Hartwig NG; Niehues T; De Groot R; Burger DM
    J Acquir Immune Defic Syndr; 2005 May; 39(1):63-8. PubMed ID: 15851915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children.
    Wintergerst U; Hoffmann F; Jansson A; Notheis G; Huss K; Kurowski M; Burger D
    J Antimicrob Chemother; 2008 Jun; 61(6):1336-9. PubMed ID: 18343800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.
    Scarsi KK; Darin KM; Nakalema S; Back DJ; Byakika-Kibwika P; Else LJ; Dilly Penchala S; Buzibye A; Cohn SE; Merry C; Lamorde M
    Clin Infect Dis; 2016 Mar; 62(6):675-682. PubMed ID: 26646680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical benefit of interventions driven by therapeutic drug monitoring.
    Rendón A; Núñez M; Jiménez-Nácher I; González de Requena D; González-Lahoz J; Soriano V
    HIV Med; 2005 Sep; 6(5):360-5. PubMed ID: 16156885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
    La Rosa AM; Harrison LJ; Taiwo B; Wallis CL; Zheng L; Kim P; Kumarasamy N; Hosseinipour MC; Jarocki B; Mellors JW; Collier AC;
    Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic drug monitoring of antiretroviral therapy: current progresses and future directions.
    Cattaneo D; Gervasoni C
    Expert Rev Clin Pharmacol; 2024 Jul; 17(7):579-587. PubMed ID: 38829318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.